NCT01037192

Evaluating the Use of Large-dose, Extended Interval Vancomycin Intravenous Administration for Skin and Soft Tissue Infections

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Fraser Health · Academic / Other
• Sex: All
• Age: 19 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Our hypothesis is that large-dose, extended-interval vancomycin (30 mg/kg IV q24h) administration provides non-inferior clinical efficacy and microbiological efficacy to standard vancomycin (15 mg/kg IV q12h) administration for skin and soft tissue infections in an outpatient setting.

Conditions

• Skin and Soft Tissue Infections

Interventions

Type	Name	Description
DRUG	vancomycin	vancomycin 30 mg/kg intravenous administered once daily
DRUG	vancomycin	vancomycin 15 mg/kg intravenous administered twice daily (standard dosing)

Timeline

• Start date: 2010-03-01
• Primary completion: 2010-09-01
• Completion: 2010-09-01
• First posted: 2009-12-22
• Last updated: 2015-08-27
• Results posted: 2011-07-08

Locations

1 site across 1 country: Canada